Dr. Patrick Y. Lu
About Dr. Patrick Y. Lu
Chairman of the Board and CEO at Sirnaomics
Dr. Patrick Y. Lu serves as the Chairman of the Board, Executive Director, President, and Chief Executive Officer at Sirnaomics. Under his leadership, Sirnaomics has progressed from an early discovery startup to a company focused on siRNA therapeutics. Dr. Lu's strategic vision and direction have been key in the company's growth and advancement within the nucleic acid drug development industry.
Experience in Nucleic Acid Drug Development
With over 25 years of experience in nucleic acid drug development, Dr. Patrick Y. Lu brings a wealth of knowledge to Sirnaomics. His extensive background includes positions at major biotech companies such as Novartis, Digene, and Intradigm. Notably, he co-founded Intradigm, showcasing his entrepreneurial skills and deep understanding of the biotech sector.
Fundraising Achievements
Dr. Patrick Y. Lu has been instrumental in helping Sirnaomics raise over $270 million in funding. His ability to secure financial resources has been critical in supporting the company's research and development efforts. This financial backing has enabled Sirnaomics to continue its pioneering work in siRNA therapeutics.
Development of siRNA Therapeutic STP705
One of Dr. Patrick Y. Lu's significant contributions to Sirnaomics is the development of the novel siRNA therapeutic, STP705. This therapeutic is designed for the treatment of cancer and fibrosis diseases. STP705 represents a major advancement in the field of siRNA therapeutics, highlighting Dr. Lu's expertise and innovative approach to drug development.